Brainstorm Cell Therapeutics

$4.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (+2.22%) Today

+$0.05 (+1.20%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BCLI and other stocks, options, and ETFs commission-free!

About BCLI

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ. The listed name for BCLI is Brainstorm Cell Therapeutics Inc. Common Stock.

CEO

Chaim Lebovits

Employees

Headquarters

New York, New York

Founded

2000

Market Cap

157.21M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.46M

High Today

$4.21

Low Today

$4.05

Open Price

$4.20

Volume

533.44K

52 Week High

$17.95

52 Week Low

$3.80

BCLI Earnings

-$0.43

-$0.29

-$0.14

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 6, Pre-Market